Monday, June 27, 2011
Keeping busy
Ella turns 3 on Wednesday and I just can't believe it. We had a little party for her at home, and we'll have another little one here on Wednesday. The twins had their 15mo. checkup last week and 3 of their 4 ears had infections. The doctor told me that a lot of kids with CF ended up getting tubes at some point because the thick mucus their bodies produces makes it hard for infections to drain appropriately from the sinuses. (that was from the pediatrician, not the CF docs) Drew has had the same infection for about 5 weeks now. It gets better and but never seems to really go away and then comes back with a vengeance a few days after the antibiotic end. We just finished up Azithromyacin and are hoping that we finally got it. I guess we'll see in a week when we go back for a follow up check!
- Posted using BlogPress from my iPad
Friday, June 17, 2011
Parent TOUCH Program
Inflammation
Tuesday, June 14, 2011
Clinic Visit
As it turned out, the doctor who I saw was the one who gave us the official diagnosis of CF back in the NICU a little over a year ago. He remembered me. He was a nice enough guy, but it rubbed me the wrong way a little when he was explaining Drew's malacia to me, as if I hadn't been dealing with it since birth and was way more familiar with his sound and anatomical abnormality than he would ever be. He thought everything looked and sounded alright, and decided not to treat things until e get the culture back. I guess we'll see. My fingers are crossed that the pseudomonas is gone, but it wouldn't be a total surprise if it shows up.
We're about to start some summer vacations in the next week or so. My mom is coming out next week for the week to both visit and provide childcare because the Yankees will be in town and we've got tickets to all 3 games. Then she will be driving with me and the kids back to PA until after the 4th. I'm hoping to make some plans to meet friends for lunches or dinners or drinks or whatever. I'm sure the week will just fly by. Martin is flying out at some point to join us and make the drive back home. After that, Ella has a couple of summer camps and then we're driving to Charleston, SC for a Moore family vacation. I hear it's hot in Charleston, yet I picked August to go. Hopefully the company of cousins will keep the kids happy and the pool and the ocean will keep us all cool.
I haven't posted out final numbers yet from the walks because we're not 100% totaled up, but I will soon. It was a great year overall, and I'm already planning to top it next year!
- Posted using BlogPress from my iPad
Location:Presidio Ct,Cincinnati,United States
Thursday, June 9, 2011
Another step in the right direction, and our Great Strides dollars hard at work!
Phase 2 Study of Two Potential CF Therapies — VX-770 and VX-809 — Shows Promising Results in Patients with Most Common Mutation
June 9, 2011
Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective protein that causes cystic fibrosis.
The study enrolled 62 people with two copies of the most common CF mutation, known as Delta F508. The trial lasted three weeks. Participants took VX-809 for two weeks, and VX-809 and VX-770 together for a third week.
Patients who took the drug regimen showed a positive change in sweat chloride levels. Excessive sweat chloride is a key clinical indicator of cystic fibrosis. The findings suggest that VX-809 and VX-770 together improve function of the defective CF protein, known as CFTR.
“The results of this study represent a milestone in our efforts to expand the use of small molecules to attack the root cause of cystic fibrosis in those with the most common defect,” said Robert J. Beall, Ph.D., president and CEO of the CF Foundation. “These data, while early, provide important new information that validates our approach and supports continued study of a combination-therapy approach to treating the basic defect of cystic fibrosis.”
The CF Foundation worked with Vertex to discover VX-770 and VX-809, and has provided substantial scientific, financial and clinical support throughout the development process, including an approximately $75 million investment.
These positive results support further testing of VX-770 and VX-809 as a combination therapy. Vertex plans to initiate the second part of this Phase 2 study in the fourth quarter of 2011.
In people with the Delta F508 mutation, the defective protein does not move to its proper place at the cell surface. VX-809 is designed to help the protein reach the cell surface, while VX-770 aims to help the protein function more normally once it is at the cell surface.
Tuesday, June 7, 2011
Today I'm just down
If you have a moment to help, it could make a big difference
On June 14th, National Institutes of Health (NIH) Director Dr. Francis S. Collins will join CF Foundation President and CEO Dr. Bob Beall and Vertex Pharmaceuticals Chairman and CEO Matthew Emmens on Capitol Hill for a roundtable discussion with Members of the House of Representatives to discuss new research initiatives NIH is using to accelerate the development of therapies. The speakers will also highlight how the successful partnership between the Cystic Fibrosis Foundation and Vertex Pharmaceuticals on VX-770 can serve as an example for federal government programs. We need as many Representatives as possible attend this event to enable the CF Foundation and Vertex Pharmaceuticals to increase awareness about cystic fibrosis and share how our successes can be replicated by NIH to help those with other illnesses.
Please call your state’s Representatives today and ask them to attend. Attached, you will find a list of Representatives who are being targeted in particular (along with their DC office phone numbers), but please feel free to contact as many of your state’s Representatives as you can. Contact information for all of your state’s Representatives is available through http://www.cff.org/
Below, you will find the information you will need for your calls:
· Talking points
· Event details
· An additional copy of the target list
If the Representative’s office would like more information, you can send them the attached flyer announcing the briefing, or tell them to contact Stephanie Krenrich in the Public Policy Department at (301) 907-2512 or skrenrich@cff.org. If you need more information, you should contact Stephanie as well.
With your help, we will make this an event to remember.
The past few decades have brought exciting scientific breakthroughs necessary to understand,
diagnose, and treat many diseases. However, the ability to translate exciting advancements into treatments that can help patients severely lags behind the pace of innovation. On average, it takes 15 years to turn a scientific discovery into a viable therapy. For the millions of Americans who live with chronic and fatal diseases, this is simply too long to wait.
TALKING POINTS
When you call, please ask for the Representative’s legislative assistant for healthcare issues. When you are connected either to the individual or their voicemail, please use these talking points as a guide:
1) As a constituent personally affected by cystic fibrosis, I wanted to invite [Representative x] to a briefing hosted by the Cystic Fibrosis Foundation and Vertex Pharmaceuticals with Dr. Francis Collins, the Director of the National Institutes of Health, on Tuesday, June 14th at 9am in room 2218 of the Rayburn House Office Building.
2) Dr. Collins will discuss “translational science” programs at NIH, which aid the translation of basic medical research into new treatments for patients
3) These initiatives have the potential to speed the development of much-needed medications for some of our most serious illnesses
4) Speakers will also discuss the successful partnership between the Cystic Fibrosis Foundation and Vertex Pharmaceuticals on new cystic fibrosis therapies as an example of how strategies NIH uses have been successful in the private and non-profit sectors
5) Would you like me to email you some more information? [If yes, ask for email address and follow up with the attached briefing announcement]
-or-
Please call Stephanie Krenrich at the Cystic Fibrosis Foundation at 301- 907-2512 for more information.
6) This briefing promises to be a constructive discussion on the best way to spur the development of new treatments for disease, and we hope that Representative x will attend. Thank you for your consideration.
EVENT DETAILS
Roundtable Discussion with NIH Director Francis S. Collins: Leveraging Federal Investment to Speed the Development of Promising Therapies for Patients
WHEN: Tuesday, June 14, 2011
9:00 am – 10:00 am
WHERE: 2218 Rayburn House Office Building
SPEAKERS:
· Francis S. Collins, M.D., Ph.D., Director, National Institutes of Health
· The Honorable Brian Bilbray, Edward Markey, and Cliff Stearns, Members of Congress
· Robert J. Beall, Ph.D., President and Chief Executive Officer, Cystic Fibrosis Foundation
· Matthew Emmens, Chairman and Chief Executive Officer of Vertex Pharmaceuticals
· Eric Olson, Ph.D., Vice President, Cystic Fibrosis Franchise Lead, Vertex Pharmaceuticals
INVITEES: Representatives (plus 1 staff)
TOPIC: NIH’s translational science programs, including NIH’s proposed National Center for Advancing Translational Sciences (NCATS), which have the potential to accelerate the development of much-needed treatments for some of our most serious illnesses. In addition, the event will feature the successful collaboration between the Cystic Fibrosis Foundation and Vertex Pharmaceuticals on promising new cystic fibrosis therapies, as an example of how the strategies to be employed by NCATS have been successful in similar situations in the private and non-profit sectors.
TARGET LIST
Alaska: Representative Don Young (R-AK-AL)
Arizona: Representative Paul Gosar (R-AZ-1)
California: Representative Mary Bono Mack (R-CA-45) (202) 225-5330
Representative Lois Capps (D-CA-23)
Representative Susan Davis (D-CA-53)
Representative Howard “Buck” McKeon (R-CA-25) (202) 225-1956
Representative Lucille Roybal-Allard (D-CA-34) (202) 225-1766
Colorado: Representative Diana DeGette (D-CO-1)
Connecticut: Representative Rosa DeLauro (D-CT-3)
Florida: Representative Mario Diaz-Balart (R-FL-21) (202) 225-4211
Representative Debbie Wasserman-Schultz (D-FL-20) (202) 225-7931
Representative C.W. Bill Young (R-FL-10) (202) 225-5961
Georgia: Representative Paul Broun (R-GA-10)
Representative Phil Gingrey (R-GA-11)
Representative Tom Price (R-GA-6)
Idaho: Representative Mike Simpson (R-ID-2)
Indiana: Representative Larry Bucshon (R-IN-8)
Louisiana: Representative Bill Cassidy (R-LA-6)
Representative John Fleming (R-LA-4)
Maryland: Representative Andy Harris (R-MD-1)
Massachusetts: Representative Mike Capuano (D-MA-8)
Representative Jim McGovern (D-MA-3)
Michigan: Representative Fred Upton (R-MI-6)
Representative John Dingell (D-MI-15)
Representative Dan Benishek (R-MI-1)
Representative Sander Levin (D-MI-12)
Minnesota: Representative Betty McCollum (D-MN-4) (202) 225-6631
Montana: Representative Denny Rehberg (R-MT-AL)
New Jersey: Representative Leonard Lance (R-NJ-7) (202) 225-5361
Representative Frank Pallone (D-NJ-6)
Representative Rush Holt (D-NJ-12)
Representative Bill Pascrell (D-NJ-8)
Nevada: Representative Joe Heck (R-NV-3)
New York: Representative Eliot Engel (D-NY-17)
Representative Nita Lowey (D-NY-18)
Representative Nan Hayworth (R-NY-19)
Representative Joe Crowley (D-NY-7)
North Carolina: Representative Sue Myrick (R-NC-9)
Pennsylvania: Representative Tom Marino (R-PA-10)
Representative Tim Murphy (R-PA-18)
Representative Joe Pitts (R-PA-16) (202) 225-2411
Representative Charlie Dent (R-PA-15)
Representative Allyson Schwartz (D-PA-13)
Tennessee: Representative Marsha Blackburn (R-TN-7)
Representative Phil Roe (R-TN-1)
Representative Scott DesJarlais (R-TN-4)
Texas: Representative Michael Burgess (R-TX-26)
Representative Ron Paul (R-TX-14)
Washington: Representative Norm Dicks (D-WA-6)
Representative Dave Reichert (R-WA-8)
Wisconsin: Representative Tammy Baldwin (D-WI-2)
Sunday, June 5, 2011
Advocacy
Reds game FAIL
We took a family trip to the Reds game yesterday. It very well might have been the #1 least pleasurable experience of my life. It was 97 degrees and we had to park blocks away from the stadium. We didn't get there until almost the 5th inning and we were gone by the 7th. We were seated 3 rows from the sun and had only bought 2 tickets. The place was damn near sold out so we were three kids and 2 adults sweating profusely in 2 small stadium seats. We had to take the stroller because there's no other way to transport the twins, but we checked it at guest services. The hike up the the nosebleed section was not easy. We took snacks and drinks with us but it didn't do the trick for anyone. Next time (said loosely) I would definitely buy 5 tickets and wouldn't go anytime after probably early May. I love so much when the 5 of us get out and do things together because it doesn't happen often, but this wasn't exactly the picture of a good time. Oh well, lesson learned.
Drew has another ear infection. I guess the first one never really went away. It takes him longer to clear secretions in general so an ear infection is really no different. We're trying Omnicef now. The girls both have summer colds so I'm hoping that if Drew catches what they've got that he can deal with it just like anyone else deals with a virus because he's already on antibiotics which should eliminate the possibility of the funk turning into bacteria and landing us on even more meds. I guess we'll see.
I'm working on our "plan" for vacation this summer. We are driving to Charleston, South Carolina and I need to make sure that I have all the appropriate meds and equipment and contact information and the scoop on local resources, should we need any of it. We aren't going until August, but it will be Drew's first big trip and time away from home and I wanna make sure that it's enjoyable and easy and if I have a plan and my ducks in a row we should be good.
Thats about all we've got going on around here these days. Nothing to exciting, and I'm okay with that.
- Posted using BlogPress from my iPad